Both primary and all key secondary efficacy endpoints showed statistically significant improvements with oral Zeposia versus placebo at Week 10 and Week 52.
Bristol Myers Squibb announced results from True North, a pivotal Phase 3 trial evaluating oral Zeposia (ozanimod) as an induction and maintenance therapy for adult patients with moderate to severe ulcerative colitis.